| Symposium 1: New trends in European contraception (Schering) | ||
| Contraceptive use in European women: a research survey on contemporary behaviour | S. Skouby (Denmark) | Abstract |
| Long-term contraception in young women: special focus on nulliparous women and contraception following abortion | A. Gebbie (UK) | Abstract |
| Contraception as a therapeutic option in the treatment of menorrhagia | H. Critchley (UK) | Abstract |
| The non-contraceptive benefits and acceptability of Yasmin® | D. Mansour(UK) | Abstract |
| Yasmin® and the extended cycle regimen: current experience | M. Sillem (Germany) | Abstract |
|
||
| Symposium 2: The Vagina Dialogue: NuvaRing® and the benefits of vaginal administration (Organon) | ||
| Women and their vaginas | G. Liekens (Belgium) | no abstract |
| The clinical profile of NuvaRing, update on new results | S. Killick (UK) | no abstract |
| NuvaRing and the beauty of vaginal administration | R. Arias (United States) | no abstract |
|
|
||
| Symposium 3: Customizing care… The art and science of low dose OC prescribing (Wyeth Pharmaceuticals) | ||
| Oral contraceptive side effects: impact of estrogen dose when selecting an oral contraceptive | P. Darney | Abstract |
| Acceptability, safety and premenstrual symptomatology in women using an oral contraceptive containing gestodene 60mcg/ethinylestradiol 15mcg | I. Barbosa | Abstract |
|
|
||
| Symposium 4: Estrogen-free contraception: the evolution of depot medroxyprogesterone acetate (Pfizer) | ||
| Hormonal contraception without estrogen: nondaily options | A. Glasier (UK) | no abstract |
| Expanding low-dose options in contraception | C. Brucker (Germany) | no abstract |
| Maximizing contraceptive convenience: managing expectations | I. Milsom (Sweden) | no abstract |
|
|
||
| Symposium 5: Contraception: why change? (Janssen-Cilag) | ||
| Contraception: are we keeping up? | M. O'Flynn (Rep. of Ireland) | no abstract |
| The transdermal route: what is it delivering? | C. Keck (Germany) | no abstract |
| Where do we go from here? | J. Guillebaud (UK) | no abstract |
|
|
||